Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hepatology ; 75(4): 898-911, 2022 04.
Article in English | MEDLINE | ID: mdl-34559897

ABSTRACT

BACKGROUND AND AIM: Portal vein thrombosis (PVT) is a common complication of cirrhosis. The exact pathophysiology remains largely unknown, and treatment with anticoagulants does not lead to recanalization of the portal vein in all patients. A better insight into the structure and composition of portal vein thrombi may assist in developing strategies for the prevention and treatment of PVT. APPROACH AND RESULTS: Sixteen prospectively and 63 retrospectively collected nonmalignant portal vein thrombi from patients with cirrhosis who underwent liver transplantation were included. Histology, immunohistochemistry, and scanning electron microscopy were used to assess structure and composition of the thrombi. Most recent CT scans were reanalyzed for thrombus characteristics. Clinical characteristics were related to histological and radiological findings. All samples showed a thickened, fibrotic tunica intima. Fibrin-rich thrombi were present on top of the fibrotic intima in 9/16 prospective cases and in 21/63 retrospective cases. A minority of the fibrotic areas stained focally positive for fibrin/fibrinogen (16% of cases), von Willebrand factor (VWF; 10%), and CD61 (platelets, 21%), while most of the fibrin-rich areas stained positive for those markers (fibrin/fibrinogen, 100%; VWF, 77%; CD61, 100%). No associations were found between clinical characteristics including estimated thrombus age and use of anticoagulants and presence of fibrin-rich thrombi. CONCLUSION: We demonstrate that PVT in patients with cirrhosis consists of intimal fibrosis with an additional fibrin-rich thrombus in only one-third of cases. We hypothesize that our observations may explain why not all portal vein thrombi in patients with cirrhosis recanalize by anticoagulant therapy.


Subject(s)
Thrombosis , Venous Thrombosis , Anticoagulants/therapeutic use , Fibrin/therapeutic use , Fibrinogen , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/drug therapy , Portal Vein , Retrospective Studies , Thrombosis/etiology , Venous Thrombosis/complications , von Willebrand Factor
2.
Science ; 300(5620): 795-8, 2003 May 02.
Article in English | MEDLINE | ID: mdl-12730600

ABSTRACT

Transmembrane helices of integrin alpha and beta subunits have been implicated in the regulation of integrin activity. Two mutations, glycine-708 to asparagine-708 (G708N)and methionine-701 to asparagine-701, in the transmembrane helix of the beta3 subunit enabled integrin alphaIIbbeta3 to constitutively bind soluble fibrinogen. Further characterization of the G708N mutant revealed that it induced alphaIIbbeta3 clustering and constitutive phosphorylation of focal adhesion kinase. This mutation also enhanced the tendency of the transmembrane helix to form homotrimers. These results suggest that homomeric associations involving transmembrane domains provide a driving force for integrin activation. They also suggest a structural basis for the coincidence of integrin activation and clustering.


Subject(s)
Cell Membrane/chemistry , Platelet Glycoprotein GPIIb-IIIa Complex/chemistry , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Protein Structure, Secondary , Amino Acid Sequence , Amino Acid Substitution , Animals , Antibodies, Monoclonal/metabolism , Biopolymers , CHO Cells , Cell Adhesion , Cricetinae , Cricetulus , Dimerization , Fibrinogen/metabolism , Fluorescein-5-isothiocyanate , Focal Adhesion Protein-Tyrosine Kinases , Ligands , Microscopy, Fluorescence , Molecular Sequence Data , Mutation , Phosphorylation , Platelet Glycoprotein GPIIb-IIIa Complex/genetics , Protein Conformation , Protein Structure, Tertiary , Protein-Tyrosine Kinases/metabolism , Receptor Aggregation
SELECTION OF CITATIONS
SEARCH DETAIL
...